Overview
Doximity fiscal Q1 revenue rises 15% yr/yr, beating analyst expectations
Adjusted EPS for fiscal Q1 beats consensus, reflecting strong financial performance
Adjusted EBITDA up 21% yr/yr, surpassing analyst forecasts
Outlook
Doximity sees Q2 revenue between $157 mln and $158 mln
Doximity expects Q2 adjusted EBITDA between $87 mln and $88 mln
Doximity updates FY2026 revenue guidance to $628 mln-$636 mln
Doximity projects FY2026 adjusted EBITDA between $341 mln and $349 mln
Result Drivers
AI SUITE GROWTH - Doximity's AI suite grew fivefold year-over-year, driving revenue increase
PRESCRIBER ENGAGEMENT - Over 630,000 prescribers used workflow tools, enhancing service efficiency
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$145.91 mln
$139.50 mln (18 Analysts)
Q1 Adjusted EPS
Beat
$0.36
$0.3 (16 Analysts)
Q1 Net Income
$53.32 mln
Q1 Adjusted EBITDA
Beat
$79.80 mln
$71.60 mln (17 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Doximity Inc is $65.00, about 10.6% above its August 6 closing price of $58.13
The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 41 three months ago
Press Release: ID:nBw7nLN87a
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)